A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma

Inclusion Criteria: * Patients with previously treated or newly diagnosed follicular center cell grade I or grade II lymphoma, small lymphocytic lymphoma, MALT lymphoma, monocytoid B-cell lymphoma, Waldenstrom's macroglobulinemia, or marginal zone lymphoma with bidimensionally measurable disease; * Part of the resected specimen must undergo routine pathologic examination to confirm the diagnosis of lymphoma. The remaining tissue must be used for the preparation of autologous HSPPC-96; * Autologous HSPPC-96 vaccine must be successfully prepared and provided by the sponsor; * A minimum of 2 grams of non-necrotic, resectable malignant lymphoma for HSPPC-96 preparation; * Bidimensionally measurable disease in at least one location other than the resected lymphoid tissue; * Life expectancy of at least 16 weeks; * Zubrod performance status of less then or equal to 2; * Adequate bone marrow function; * Adequate hepatic function; * Adequate renal function; * Signed written informed consent; * Patients of child-bearing potential must practice contraception, which is adequate in the opinion of the Principal Investigator; * Patients of child-bearing potential must have a negative serum pregnancy test prior to entry into the study and must not be lactating; * Patients must be willing to be followed at the M. D. Anderson Cancer Center during the course of treatment and follow-up; * Electrocardiogram if none performed in the prior six months; * Patients must have no chemotherapy, immunoth…